Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2023-04-20 Director's Dealing
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Miriam Kidron
Director's Dealing Classification · 95% confidence The document is a short filing (1880 chars) submitted to the Israel Securities Authority (ISA) and Tel Aviv Stock Exchange (TASE). It explicitly states, 'Attached hereto is a report on *Form_4_-_Miriam_Kidron_-_April_19_2023_isa.pdf*'. A Form 4 filing in the US context relates to insider transactions (directors' dealings). Since this document is an announcement pointing to an attached report about a director's transaction (Miriam Kidron), and given the short length and announcement nature, it fits the criteria for a Director's Dealing report, but the document itself is the *announcement* of that report. However, the provided definitions do not have a specific code for a US Form 4 filing. The closest conceptual match is 'Director's Dealing' (DIRS). Since this is an announcement referencing an attached document (Form 4), and not the full text of a DIRS report, it could potentially be RPA or RNS based on the 'MENU VS MEAL' rule. But DIRS is a specific category for director transactions. Given that the content is explicitly about a director's transaction filing (Form 4), DIRS is the most accurate thematic classification, even if it's an announcement wrapper. If DIRS is interpreted as the actual report content, then RPA/RNS applies. Since the document is clearly referencing a specific insider transaction report (Form 4), I will classify it as DIRS, assuming the wrapper is acceptable for this specific type of regulatory filing announcement.
2023-04-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Hexter Joshua
Director's Dealing Classification · 100% confidence The document explicitly begins with the header "FORM 4" and "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES". Form 4 is a mandatory SEC filing used by corporate insiders (directors, officers, or 10% owners) to report changes in their beneficial ownership of the company's securities. This directly corresponds to the definition of Director's Dealing (insider trades), which is categorized under the code DIRS in the provided schema.
2023-04-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Hexter Joshua
Director's Dealing Classification · 98% confidence The document explicitly states it is an 'Other Report or Announcement' under Israeli regulations and attaches a report titled 'Form 4 - Josh Hexter'. Form 4 in the US context (and often referenced in filings by foreign private issuers like this one, Oramed Pharmaceuticals Inc.) is used to report insider transactions (changes in beneficial ownership of securities by directors, officers, or 10% owners). This directly corresponds to the definition of Director's Dealing (insider trades). The filing type code for Director's Dealing is DIRS. The document is short and appears to be an announcement attaching the actual Form 4 filing, but since Form 4 itself is the core content being reported, and DIRS covers reports of personal share transactions by directors, DIRS is the most specific classification, overriding the general RPA/RNS fallback, unless the document was purely a notice *about* the filing date. Given the content structure, it is reporting the transaction via the attachment.
2023-04-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Mayer Arie
Director's Dealing Classification · 100% confidence The document explicitly begins with "FORM 4" and the header "UNITED STATES SECURITIES AND EXCHANGE COMMISSION". It details a "STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES" filed pursuant to Section 16(a) of the Securities Exchange Act of 1934. This form (Form 4) is used by insiders (directors, officers, or 10% owners) to report personal share transactions. This directly corresponds to the definition of Director's Dealing (insider trades). Reviewing the provided definitions, 'Director's Dealing' (Code: DIRS) is the most accurate classification for a Form 4 filing.
2023-04-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Mayer Arie
Director's Dealing Classification · 98% confidence The document explicitly mentions 'Form 4 - Arie Mayer' and includes details about a signatory (DEROVAN NETANEL MOSHE, Chief Legal Officer & Secretary) and their transaction/reporting context. Form 4 filings in the US context (implied by NASDAQ CM listing and US address) are used to report insider transactions (changes in beneficial ownership by directors, officers, or principal stockholders). This directly corresponds to the definition of Director's Dealing (insider trades). The filing is not a full annual report (10-K), an earnings release (ER), or a general announcement of a report (RPA/RNS), but a specific regulatory filing detailing insider transactions.
2023-04-20 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES-Sank Leonard
Director's Dealing Classification · 100% confidence The document explicitly begins with '# **FORM 4**' and is titled 'STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES'. This form is filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 by directors, officers, or 10% owners regarding transactions in company securities. This specific filing type relates to insider trading/executive transactions, which corresponds to the 'Director's Dealing' category in the provided definitions.
2023-04-20 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.